MAPT and Alzheimer disease: On the other hand, Cerebrolysin® and the combination therapy were also found to reduce circulating TNF-α in AD patients [50, 63], and baseline NDEV total tau showed positive correlations with plasma TNF-α in the NDEV Study and in the RCT (r = 0.299, p = 0.002).